Article Text

Download PDFPDF
Response to ‘Correspondence on ‘Impact of the COVID-19 pandemic on the disease course of patients with inflammatory rheumatic diseases: results from the Swiss Clinical Quality Management cohort’ by Ruyssen-Witrand et al
  1. Adrian Ciurea1,
  2. Axel Finckh2
  1. 1 Rheumatology, University Hospital Zurich, Zurich, Switzerland
  2. 2 Division of Rheumatology, Geneva University Hospitals, Geneve, Switzerland
  1. Correspondence to Professor Adrian Ciurea, Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland; adrian.ciurea{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

We would like to thank Ruyssen-Witrand et al for their interest in our study1 and their data from French patients with rheumatoid arthritis collected during the first wave of the COVID-19 pandemic through an online survey.2 Despite the fact that up to 70% of medical consultations could not be performed as …

View Full Text


  • Handling editor Josef S Smolen

  • Contributors AC and AF wrote the manuscript and approved the final version.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests AC reports personal fees from AbbVie, Celgene, Eli Lilly, Merck Sharp & Dohme, Novartis and Pfizer, outside the submitted work.

  • Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

  • Provenance and peer review Commissioned; internally peer reviewed.

Linked Articles